Vivaldi Coelho Rogerio 4

What Happened

• Director Vivaldi Coelho Rogerio reported the sale of a total of 5,000 shares of Crinetics Pharmaceuticals (CRNX) in two open-market transactions on March 12, 2026, generating approximately $180,761 in proceeds (4,477 shares for $161,530 and 523 shares for $19,231). These were sales (not purchases) and therefore represent disposition of existing holdings rather than an acquisition.

Key Details

• Transaction dates: March 12, 2026; Form 4 filed March 13, 2026 (timely filing).
• Prices and values:
  • 4,477 shares sold at a volume-weighted average price (VWAP) of $36.08; reported proceeds $161,530. Intraday price range that day: $35.65–$36.53. (Footnote F2)
  • 523 shares sold at a VWAP of $36.77; reported proceeds $19,231. Intraday price range that day: $36.69–$36.89. (Footnote F3)
• Total shares sold: 5,000; total proceeds: ~$180,761.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Notable footnote: Sales were executed automatically under a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2025. (Footnote F1)
• Filing timeliness: Report appears timely (filed the day after the trades).

Context

• A 10b5-1 plan indicates the trades were prearranged and executed according to an automated schedule, which is commonly used by insiders to avoid trading on nonpublic information; such sales are often considered routine and not necessarily a signal of management’s view on the company's prospects.
• For retail investors, purchases typically carry more weight as bullish signals than routine sales; here, the disclosure documents a routine, preplanned sale of existing shares.